Related Experiment Video
Updated: Jun 13, 2026
11:17
Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses
Published on: August 30, 2018
[Drug-drug interactions in multicentre polypathological polymedicated patients]
J Galindo-Ocaña1, M V Gil-Navarro, J S García-Morillo
1Unidad Clínica de Atención Medica Integral, Servicio de Medicina Interna, Hospitales Universitarios Virgen del Rocío, Sevilla, España. galinx2@gmail.com <galinx2@gmail.com>
Revista Clinica Espanola
|May 4, 2010
Summary
Nearly all patients with multiple chronic diseases experience drug-drug interactions (DDIs). A collaborative approach to managing these DDIs can improve prescription safety and patient outcomes.
Area of Science:
- Pharmacology
- Clinical Pharmacy
- Geriatrics
Context:
- Polypathological patients on multiple drug therapy are at high risk for drug-drug interactions (DDIs).
- Primary care settings present unique challenges for managing complex medication regimens.
- Understanding the prevalence and predictors of DDIs is crucial for patient safety.
Purpose:
- To determine the prevalence of relevant drug-drug interactions (DDIs) in polypathological patients receiving multiple medications.
- To identify factors associated with the occurrence of DDIs in this population.
- To assess the acceptance of a DDI reporting program by prescribing physicians.
Summary:
- A cross-sectional study identified 1053 DDIs among 283 polypathological patients, with 45% deemed relevant.
- Ischemic heart disease, multiple hospital admissions, and polypharmacy were associated with increased DDIs.
- Physicians favorably accepted 84% of DDI recommendations provided by the pharmacy department.
Impact:
- Almost all polypathological, polymedicated patients are exposed to at least one DDI.
- Targeted interventions and personalized recommendations can improve the risk-benefit ratio of drug prescriptions.
- Collaborative efforts between pharmacists and physicians are essential for optimizing medication management in complex patients.
Related Concept Videos
01:30Drug toxicity: Drug–Drug Interaction
Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
01:25Pharmacokinetics: Drug–Drug Interactions
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:24Drug Toxicity: Risk factors
Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...